1. Home
  2. BGSF vs HYFT Comparison

BGSF vs HYFT Comparison

Compare BGSF & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

N/A

Current Price

$5.63

Market Cap

64.0M

ML Signal

N/A

HYFT

MindWalk Holdings Corp.

HOLD

Current Price

$1.46

Market Cap

71.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
HYFT
Founded
2007
1983
Country
United States
United States
Employees
N/A
102
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.0M
71.9M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
BGSF
HYFT
Price
$5.63
$1.46
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
6.9K
256.4K
Earning Date
05-06-2026
03-12-2026
Dividend Yield
36.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$93,310,000.00
N/A
Revenue This Year
$4.67
N/A
Revenue Next Year
N/A
$29.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.26
$0.99
52 Week High
$8.20
$3.00

Technical Indicators

Market Signals
Indicator
BGSF
HYFT
Relative Strength Index (RSI) 50.20 47.59
Support Level $5.49 $1.40
Resistance Level $5.79 $1.96
Average True Range (ATR) 0.15 0.11
MACD -0.02 -0.02
Stochastic Oscillator 18.18 38.19

Price Performance

Historical Comparison
BGSF
HYFT

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.

About HYFT MindWalk Holdings Corp.

MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

Share on Social Networks: